Revenio Group Corporation:Proposals to Annual General Meeting concerning the number of Board Members, their remuneration and reimbursement of their costs, and nomination of the Board Members
Revenio Group Corporation, Stock Exchange Release, February 29, 2016 at 9:00
PROPOSALS TO ANNUAL GENERAL MEETING CONCERNING THE NUMBER OF THE BOARD MEMBERS, THEIR REMUNERATION AND REIMBURSEMENT OF THEIR COSTS, AND NOMINATION OF THE BOARD MEMBERS
Shareholders of Revenio Group Corporation, accounting for a total of 18.03 percent of all shares and voting rights in the Company have informed the Company that they will present at the Annual General Meeting held on March 15, 2016 the following proposals regarding the items A10, A11 and A12 on the Notice of the Annual General Meeting:
A 10 Resolution on the remuneration of the members of the Board of Directors and on the grounds for compensation of travel expenses
The proposal to be presented:
To the Board of Directors to be elected at the AGM for the term until the close of the AGM in 2017 shall be paid as follows: EUR 48,000 for the Chairman and EUR 24,000 for the members of the Board of Directors. Additionally it is proposed that 40 percent of Board members' remunerations will be settled in the form of Company shares, while 60 percent will consist of a monetary payment.
Moreover is proposed that the travel expenses of the members of the Board of Directors be compensated in accordance with Company's travel policy.
A 11 Resolution on the number of members of the Board of Directors
The proposal to be presented:
Five regular members shall be elected to the Board of Directors.
A 12 Election of the members of the Board of Directors
The proposal to be presented:
The following members shall be re-elected to the Company's Board of Directors: Pekka Tammela, Ari Kohonen, Pekka Rönkä, Kyösti Kakkonen and Ann-Christine Sundell as a new member.
--
The introduction of Ann-Christine Sundell will be presented on the Company web page at www.revenio.fi and as an attachment to this Stock Exchange Release.
Revenio Group Corporation
Board of Directors
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.